By Marian (YoonJee) Chu | June 24, 2024
Alzheon Inc. has raised $100 million in a series E financing round to push its oral drug candidate for early Alzheimer’s disease (AD), ALZ-801 (valiltramiprosate), through a late-stage, Apolloe4 study.
On the brink of a data readout in the third quarter of 2024, Framingham, Mass.-based Alzheon is approaching regulatory filings in the U.S. this year, Martin Tolar, founder, president and CEO of Alzheon, recently told BioWorld.